RA190

RA190, a bis-benzylidine piperidon, is a potent, selective and oral effective inhibitor of proteasome ubiquitin receptor RPN13/ADRM1 with anticancer activity. RA190 triggers ER stress response, p53/p21 signaling axis and autophagy in multiple myeloma cell

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1400.00

1120.00

- +
10mg

￥2037.00

1630.00

- +
25mg

￥3125.00

2500.00

- +
50mg

￥5562.00

4450.00

- +
100mg

￥9850.00

7880.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce49772
CAS: 1617495-03-0
别名:
分子式: C28H23Cl5N2O2
分子量: 596.76
纯度: >98%
溶解度: DMSO : ≥ 100 mg/mL (167.57 mM);Water : < 0.1 mg/mL (insoluble)
储存: Store at -20°C
库存: 现货

Background

[1] Ravi K Anchoori, et al. Cancer Cell. 2013 Dec 9;24(6):791-805. [2] Y Song, et al. Leukemia. 2016 Sep;30(9):1877-86.

Protocol

Cell experiment:

RA190 is dissolved in DMSO and diluted with cell culture medium. HeLa cells are treated with RA190 (0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5 μM) for 48 hr. Cell viability is assayed using commerical kit[1].

Animal experiment:

Mice: Mice are divided into two groups and treated daily i.p. with RA190 (10 mg/kg) or vehicle, and imaged again on day 7 and day 14. NOG mice (5 per group) are inoculated with 1X106 NCI-H929-GFP-Luc cells i.v., and after 4 weeks, mice are imaged for their luciferase activity and divided into two groups. Mice are treated i.p. with RA190 (20 mg/kg) or vehicle, and imaged again at the end of the treatment for their luciferase activity[1].

参考文献:

[1]. Anchoori RK, et al. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell. 2013 Dec 9;24(6):791-805.